Drug Profile
GS 9901
Alternative Names: GS-9901Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Class Antineoplastics
- Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic lymphocytic leukaemia; Lymphoma
Most Recent Events
- 01 Dec 2014 Phase-I clinical trials in Chronic lymphocytic leukaemia and Lymphoma (Second-line therapy or greater, Refractory metastatic disease) in USA (PO) (NCT02258555)
- 08 Oct 2014 Preclinical trials in Chronic lymphocytic leukaemia in USA (PO) prior to October 2014
- 08 Oct 2014 Preclinical trials in Follicular lymphoma in USA (PO) prior to October 2014